A combination antitumor formulation comprising tetrandrine, quercetin or dihydroquercetin

Update: 30 October, 2023

A combination antitumor formulation comprising tetrandrine (TET), quercetin (QUE) or dihydroquercetin (DHQ) and a tyrosine kinase inhibitor, preferably third-generation tyrosine kinase inhibitor, more preferably osimertinib (OSI) or ametinib (ALM) is provided. In preferred embodiments, the formulation is effective against non-small cell lung cancer and more preferably, EGFR-mutant-driven tyrosine kinase inhibitor-resistant non-small cell lung cancer.

---

File format: PDF

Size: -

MD5 Checksum: 7399120AF05057BEFE65B42EEE2B0B86

Publication date: 30 October, 2023

Downloads: -

PDF Link: A combination antitumor formulation comprising tetrandrine, quercetin or dihydroquercetin PDF